Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Summary

This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma.

Timeline

Start

2011-10

Primary completion

2012-06

Completion

2012-06

Drugs

Indications